医学
无容量
彭布罗利珠单抗
舒尼替尼
肾细胞癌
免疫疗法
替西罗莫司
肾癌
肿瘤科
靶向治疗
易普利姆玛
内科学
癌症
PI3K/AKT/mTOR通路
mTOR抑制剂的发现与发展
信号转导
生物化学
化学
作者
Balqees Ara,Anum Babar,Durkho Atif,Bushra Ghafoor,Mitul Shah,Syed Maaz Abdullah,Danish Safi,Amir Kamran
标识
DOI:10.1177/10781552241289920
摘要
Renal cell carcinoma (RCC) is the most common kidney cancer, with clear cell RCC being the predominant subtype. However, non-clear cell RCC constitutes a significant proportion of cases, presenting distinct challenges in treatment due to its varied histological subtypes. Despite recent advancements, the optimal therapeutic approach for non-clear cell RCC remains uncertain due to limited high-quality evidence. This systematic review aims to evaluate the efficacy of systemic therapies in nccRCC subgroups.
科研通智能强力驱动
Strongly Powered by AbleSci AI